Product Description
TRX103 is an investigational allogeneic off-the-shelf engineered T cell product generated from CD4+ cells sourced from healthy donors. These donor-derived CD4+ cells are engineered to produce cells that mimic the function of Tr1 regulatory T cells. Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders. Multiple preclinical models of disease have shown TRX103 to be tolerable and effective and to have the potential to reset immune systems to a healthy state. TRX103 has the potential to overcome major limitations of current cell therapies for autoimmune diseases, which include limited persistence and side effects including cytokine release syndrome (CRS) and neurotoxicity. (Sourced from: https://www.benzinga.com/pressreleases/24/04/n38181165/tr1x-announces-fda-clearance-of-first-investigational-new-drug-application-for-trx103-an-allogenei)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tr1X, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TRX-103](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Lymphoid Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Adult T-Cell Leukemia-Lymphoma|B-Cell Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Juvenile Myelomonocytic Leukemia,|Lymphoma, B-Cell|Myelodysplastic Syndrome|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TRX103-01 | P1 |
Recruiting |
Acute Monocytic Leukemia|B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myelomonocytic Leukemia|Lymphoma, B-Cell|Myelodysplastic Syndrome|Graft vs Host Disease|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Hematopoietic Stem Cell Transplant|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
2026-04-15 |